A Katten team represented Deerfield Management Company, L.P. affiliates (Deerfield) in the successful sale of Melinta Therapeutics, LLC (Melinta) to CorMedix, Inc. (CorMedix) (NASDAQ:CRMD) for $300 million in the aggregate of cash and CorMedix stock, plus contingent consideration.
Katten also represented Deerfield as a lead investor in CorMedix's private placement of $150 million aggregate principal amount of convertible notes. CorMedix issued the convertible notes to help finance the Melinta acquisition.
Melinta is a commercial-stage company providing therapies for acute and life-threatening illnesses. CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions.
The Katten team that represented Deerfield was led by Partner and Co-Chair of Capital Markets Mark Wood and included Mergers and Acquisitions Partner Josh Feiger and Associate Kylie Sholty; Capital Markets Partners Elizabeth McNichol and Jonathan Weiner; Employee Benefits and Executive Compensation Partner Mitchel Pahl and Associate Neal Patel; Transactional Tax Planning Partner Jill Darrow; Intellectual Property Partner Sean Wooden; and Health Care Partner Kate Hardey.
"CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team," Stock Titan, September 2, 2025
"CorMedix completes $150 million convertible notes offering on Nasdaq," Investing.com, August 12, 2025
"Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership," Business Wire, August 7, 2025
